Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The nicotinic acetylcholine receptor (nAChR) in nematode muscle is a ligand-gated ion channel that mediates fast synaptic transmission at the neuromuscular junction. It is the primary molecular target for several classes of anthelmintic drugs, including levamisole, pyrantel, and oxantel. Activation of these receptors by agonists leads to sustained muscle contraction and ultimately spastic paralysis of the parasite. Each nAChR is a pentamer formed from five homologous subunits arranged around a central pore. Several pharmacologically distinct subtypes exist, including L-type, N-type, and B-type receptors. Key genes encoding muscle nAChR subunits include unc-29, unc-38, unc-63, lev-1, lev-8, and acr-16 in *C. elegans*.
Agonist-induced sustained activation leading to spastic paralysis
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Nicotinic Acetylcholine Receptor (Nematode Muscle) (nAChR (Nematode Muscle)).